What questions do holders want asked at the AGM?, page-73

“On the 30th September 2021 it was immediate.”

It was, and interestingly Cynata received IND approval for their new therapy quicker than another well-known Australian biotech company using a repurposed drug (and I’m not talking about little m, here).

If you want a great example of what can go wrong if you rush a clinical trial, have a read of Exopharm’s (EX1) announcement in April ‘21 when they revealed they accidentally knee-capped their mice subjects.

“Yet there hasn't been an update on the development strategy?”

There have been several updates, most recently on October 31. “With start-up activities such as negotiations with study centres underway for the Phase 2 clinical trial in aGvHD, the Company expects to open the first clinical trial site in the coming months, subject to timely ethics and administrative approvals. Results are expected in 2024.”

“All systems go on the partnering - so where is the partner?”

Likely waiting for efficacy data from the DFU trial, and any (if available) from the concluded MEND trial.